anxiety
Conditions
Interventions
This is a randomized, double-blind, crossover clinical trial with four arms, comprising three doses of Rhodiola rosea and a placebo. A total of 40 participants will be included, consisting of 20 young
Sponsors
Universidade Federal do Rio de Janeiro Campus Macaé
Universidade Federal do Rio de Janeiro Campus Macaé
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adults aged between 18 and 45 years old for young adults and above 60 years old for older adults; individuals engaged in resistance training for at least six months prior to the first study visit; with or without a diagnosis of common mental disorders (anxiety and/or depression); of both sexes
Exclusion criteria
Exclusion criteria: Osteoarthritis and rheumatoid arthritis; human immunodeficiency virus (HIV) infection; musculoskeletal disorders that prevent physical exercise; hypertension (systolic blood pressure above 120 mmHg and/or diastolic blood pressure above 80 mmHg); cardiovascular diseases; pregnancy and lactation; use of anticonvulsants; use of central nervous system stimulants, such as methylphenidate (Ritalin®, Concerta®), lisdexamfetamine (Vyvanse®, Juvene®), bupropion hydrochloride (Wellbutrin XL®, Zetron XL®, Bup), lithium carbonate (Carbolithium®); smokers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected thatRhodiola rosea at the maximal dose can improve anxiety and mood parameters in young and older adults;It is expected that Rhodiola rosea at the maximal dose can improve heart rate variability parameters in young and older adults;It is expected that Rhodiola rosea at the maximal dose can improve muscle force parameters in young and older adults | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected that Rhodiola rosea at the maximal dose can improve cognition in young and older adults | — |
Countries
Brazil
Contacts
Public ContactGustavo de Oliveira
Universidade Federal do Rio de Janeiro Campus Macaé
Outcome results
None listed